Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose
chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and …

Purpose Effective and less aggressive therapies are required for patients with relapsed or
refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for or have undergone …

For patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who are not
eligible for intensive chemotherapy because of comorbidities, advanced age, or relapse …

This single-arm phase 3 study was conducted to confirm the results of our phase 2 study of
bendamustine (B)-rituximab (R) in patients with relapsed/refractory diffuse large B cell …

Bendamustine plus rituximab (BR) showed efficacy and safety in indolent lymphomas and
mantle cell lymphoma. However, there were limited experiences of real-world practice of BR …

Patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) are treated with
salvage regimens and may be considered for high-dose chemotherapy and autologous …

8041 Background: Diffuse large B-cell lymphoma (DLBCL) accounts for 35% of all non-
Hodgkins lymphomas in western society. Current front-line chemoimmunotherapies are …

Abstract Abstract 661 Objective: To compare 131 Iodine-Tositumomab/BEAM to
Rituximab/BEAM as the conditioning regimen followed by autologous stem cell …

Aim: Despite long-term responses to first-line immunochemotherapy, many patients with
diffuse large B-cell lymphoma (DLBCL) have relapsed/refractory disease. Second-line …

Despite bendamustine-rituximab (BR) showed disappointing efficacy in diffuse large B cell
lymphoma (DLBCL), it is still occasionally used as first-line treatment in older DLBCL …